What Treatments are Available for TRK Fusion-Positive Cancers?
The primary treatment for TRK fusion-positive cancers involves the use of TRK inhibitors. Two such inhibitors, Larotrectinib and Entrectinib, have been approved for use in patients whose tumors harbor NTRK gene fusions. These drugs have demonstrated high response rates and durable effects across various cancer types. However, resistance to these inhibitors can develop, prompting ongoing research into next-generation TRK inhibitors and combination therapies.
